ORYZON to initiate ESCAPE: a Phase II clinical trial to test efficacy of vafidemstat in severely ill COVID-19 patients


• CTA approval, the European IND equivalent, granted by the Spanish Drug Agency via an accelerated procedure

• Primary endpoint: To investigate the efficacy of vafidemstat, in combination with standard of care treatment, to prevent Acute Respiratory Distress Syndrome (ARDS) in adult severely ill COVID-19 patients


Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that under certain urgency provisions related to the COVID-19 pandemic it has received approval from the Spanish Drug Agency (AEMPS) to conduct a Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients.


Click here to see the full Press Release